- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:42 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| 10:40 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 10:36 | EXTRAWELL PHAR (00858): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 10:34 | EXTRAWELL PHAR (00858): FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 22 AUGUST 2025 AT 11:00 A.M. | - | HKEx | ||
| 10:32 | EXTRAWELL PHAR (00858): PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL ... | 1 | HKEx | ||
| 10:30 | EXTRAWELL PHAR (00858): ANNUAL REPORT 2025 | 3 | HKEx | ||
| 03.07. | EXTRAWELL PHAR (00858): TERMS OF REFERENCE OF NOMINATION COMMITTEE | 1 | HKEx | ||
| 30.06. | EXTRAWELL PHAR (00858): ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2025 | 1 | HKEx | ||
| 23.06. | EXTRAWELL PHAR (00858): PROFIT ALERT | - | HKEx | ||
| 17.06. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | - | HKEx | ||
| 28.03. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 28 MARCH 2025 | - | HKEx | ||
| 13.03. | EXTRAWELL PHAR (00858): SUPPLEMENTAL ANNOUNCEMENT, PROPOSED APPOINTMENT OF AUDITOR, NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 MARCH 2025 AT 11:00 A.M. | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR AND NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 07.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR | 1 | HKEx |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 35,890 | -0,22 % | KalVista, Biogen, Ionis get EU positive opinions for key drugs | ||
| CSPC PHARMA | 1,005 | +7,07 % | CSPC PHARMA (01093): NEXT DAY DISCLOSURE RETURNS | ||
| SELLAS LIFE SCIENCES | 1,574 | +2,88 % | SELLAS Life Sciences Group, Inc.: SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study | The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,740 | -0,33 % | What Analysts Are Saying About ACADIA Pharmaceuticals Stock | ||
| MADRIGAL PHARMACEUTICALS | 254,70 | +0,20 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 | ||
| CATALYST PHARMACEUTICALS | 17,790 | -0,75 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| ENZON PHARMACEUTICALS | 0,056 | -3,48 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,002 | -0,60 % | H.C. Wainwright reiterates Buy rating on Opus Genetics stock, citing RDH12 alliance | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,019 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,280 | +4,59 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,520 | +0,80 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,870 | -1,20 % | Biodexa Pharmaceuticals: How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market | CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis (FAP) is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated,... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,664 | 0,00 % | NovaBay Pharmaceuticals, Inc. - 10-Q, Quarterly Report |
Das Unternehmen EXTRAWELL PHARMACEUTICAL HOLDINGS LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.